Pfizer's novel glaucoma candidate goes to trial

Pfizer has initiated the first in a series of planned clinical trials for PF-03187207, a new experimental medicine for the treatment of glaucoma.

Pfizer has initiated the first in a series of planned clinical trials for PF-03187207, a new experimental medicine for the treatment of glaucoma.

The Phase II, dose-finding study, will compare the safety and efficacy of PF-03187207 to latanoprost over a 28-day period. The randomized, double-masked study is expected to enrol 150 subjects with primary open angle glaucoma or ocular hypertension in one or both eyes.

PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between NicOx and Pfizer, which focuses on the research and development of nitric oxide-donating prostaglandin F2-alpha analogues for the treatment of glaucoma.

The initiation of the clinical trial follows the granting of an Investigational New Drug (IND) approval by the FDA, which in turn results in a €1 million milestone payment from Pfizer to NicOx.

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
POAG study hope to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma
Gonio-intervention robot-assisted glaucoma surgical procedure offers high precision
Related Content
© 2023 MJH Life Sciences

All rights reserved.